EWA
ALXN

Evolution Wealth Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Evolution Wealth Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-30
Closed -$6K – 694
2021
Q2 		$6K Sell
30
-71
-70% -$12.2K ﹤0.01% 491
2021
Q1 		$15K Sell
101
-173
-63% -$26.8K ﹤0.01% 350
2020
Q4 		$43K Buy
274
+14
+5% +$1.8K 0.01% 189
2020
Q3 		$30K Buy
260
+230
+767% +$24.8K 0.01% 234
2020
Q2 		$3K Buy
+30
New +$3.19K ﹤0.01% 461
2019
Q3 		– Sell
-173
Closed -$23K – 608
2019
Q2 		$23K Buy
+173
New +$22.3K 0.01% 121

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Evolution Wealth Advisors's ALXN Position: Q3 2021 in Review

Evolution Wealth Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 30 shares — an estimated $6K sold.

Evolution Wealth Advisors first reported a position in ALXN in Q2 2019 and held it in 6 quarters. The position peaked at $43K in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Evolution Wealth Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Evolution Wealth Advisors sold 30 Alexion Pharmaceuticals shares in Q3 2021, an estimated $6K.
  • Evolution Wealth Advisors first reported a position in Alexion Pharmaceuticals in Q2 2019 and held it in 6 quarters.
  • Evolution Wealth Advisors's Alexion Pharmaceuticals position peaked at $43K in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Evolution Wealth Advisors's 13F filing for Q3 2021, filed 9 Nov 2021.